Systemic therapy for primary and extragonadal germ cell tumors: Prognosis and nuances of treatment

Bilal A. Siddiqui; Miao Zhang; Louis L. Pisters; Shi Ming Tu

doi:10.21037/tau.2019.09.11

Systemic therapy for primary and extragonadal germ cell tumors: Prognosis and nuances of treatment

Bilal A. Siddiqui, Miao Zhang, Louis L. Pisters, Shi Ming Tu

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification of testicular cancers, and reviews the current state of knowledge and standard of care for the systemic treatment of testicular germ cell tumors with chemotherapy, focusing on the relevant clinical data supporting each treatment regimen. This review also briefly highlights current areas of active investigation, notably in the relapsed and refractory setting, including ongoing clinical trials.

Original language	English (US)
Pages (from-to)	56-65
Number of pages	10
Journal	Translational Andrology and Urology
Volume	9
DOIs	https://doi.org/10.21037/tau.2019.09.11
State	Published - Jan 1 2020

Keywords

Germ cell and embryonal
Neoplasms
Non-seminomatous germ cell tumor
Seminoma
Testicular germ cell tumor

ASJC Scopus subject areas

Reproductive Medicine
Urology

Access to Document

10.21037/tau.2019.09.11

Cite this

@article{ddab10340a4141b48450fd6fbdbc0bab,

title = "Systemic therapy for primary and extragonadal germ cell tumors: Prognosis and nuances of treatment",

abstract = "Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification of testicular cancers, and reviews the current state of knowledge and standard of care for the systemic treatment of testicular germ cell tumors with chemotherapy, focusing on the relevant clinical data supporting each treatment regimen. This review also briefly highlights current areas of active investigation, notably in the relapsed and refractory setting, including ongoing clinical trials.",

keywords = "Germ cell and embryonal, Neoplasms, Non-seminomatous germ cell tumor, Seminoma, Testicular germ cell tumor",

author = "Siddiqui, {Bilal A.} and Miao Zhang and Pisters, {Louis L.} and Tu, {Shi Ming}",

year = "2020",

month = jan,

day = "1",

doi = "10.21037/tau.2019.09.11",

language = "English (US)",

volume = "9",

pages = "56--65",

journal = "Translational Andrology and Urology",

issn = "2223-4683",

publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Systemic therapy for primary and extragonadal germ cell tumors

T2 - Prognosis and nuances of treatment

AU - Siddiqui, Bilal A.

AU - Zhang, Miao

AU - Pisters, Louis L.

AU - Tu, Shi Ming

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification of testicular cancers, and reviews the current state of knowledge and standard of care for the systemic treatment of testicular germ cell tumors with chemotherapy, focusing on the relevant clinical data supporting each treatment regimen. This review also briefly highlights current areas of active investigation, notably in the relapsed and refractory setting, including ongoing clinical trials.

AB - Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification of testicular cancers, and reviews the current state of knowledge and standard of care for the systemic treatment of testicular germ cell tumors with chemotherapy, focusing on the relevant clinical data supporting each treatment regimen. This review also briefly highlights current areas of active investigation, notably in the relapsed and refractory setting, including ongoing clinical trials.

KW - Germ cell and embryonal

KW - Neoplasms

KW - Non-seminomatous germ cell tumor

KW - Seminoma

KW - Testicular germ cell tumor

UR - http://www.scopus.com/inward/record.url?scp=85083876919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083876919&partnerID=8YFLogxK

U2 - 10.21037/tau.2019.09.11

DO - 10.21037/tau.2019.09.11

M3 - Review article

C2 - 32055486

AN - SCOPUS:85083876919

SN - 2223-4683

VL - 9

SP - 56

EP - 65

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

ER -

Systemic therapy for primary and extragonadal germ cell tumors: Prognosis and nuances of treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this